Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00970593 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
92
Enrollment target

NCT00970593 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 92 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00970593, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
92 participants
Enrollment target

Study Summary

This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.

Interventions

  • DRUG placebo comparator
  • DRUG OAP-189

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2009-09-02
Est. Completion 2011-07-25
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00970593

The ClinicalTrials.gov registry entry for NCT00970593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo comparator is the first listed.

NCT00970593 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00970593 about?

NCT00970593 is a clinical study titled "Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin". This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.

What is the current status of trial NCT00970593?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2009-09-02. Estimated completion is 2011-07-25.

What interventions are being tested in trial NCT00970593?

The interventions under investigation include: placebo comparator (DRUG), OAP-189 (DRUG).

Who is sponsoring clinical trial NCT00970593?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.